No abstract

Patients' perspectives correlated with the number of limited motion joints but with none of the other physicians' and para-clinical evaluations. The patients' opinion about their function should play a major role in their management.

No abstract

Rheumatoid arthritis is a systemic inflammatory disorder characterized by joint articular pain and disability. Although there is scarcity of data available on the incidence and prevalence of RA in Latin America, there is a growing recognition of this disease where chronic diseases are on the rise and infectious disease on the decline. RA is a substantial burden to patients, society, and the healthcare system. The heterogeneity identified within RA presents an opportunity for personalized medicine, especially in regions with such demographic diversity as that of Latin America. To understand the long-term effects of treatment for RA especially on safety, registries have been established, a number of which have been created in Latin America. Despite their weaknesses (e.g., lack of controls and randomization), registries have provided additional and complementary information on the use of biologics in clinical practice in Latin America and other regions. Although certain challenges remain in the implementation and maintenance of registries, they continue to provide real-life data to clinical practice contributing to improved patient care.

Background The presence of subclinical inflammation promotes the progression of morphostructural joint damage in RA patients. Currently, clinical remission is based on the count of swollen and painful joints associated with acute phase reactants. Adding an image technique like grey scale (GS) US and power Doppler (PD) increases the capability to detect active synovitis. There are no studies on the association between active synovitis as defined by PD and more specific markers of inflammation like cytokines in patients with RA in clinical remission Objectives To identify subclinical synovitis in patients with RA in clinical remission using US and to characterize the biological profile of this group of patients by determining inflammatory cytokines Methods RA patients in clinical remission according to ACR/EULAR criteria were enrolled. Clinical evaluation was performed and DAS28 calculated. Cytokines (IL1b, 10, 6. 5, 2, 4, 8, GMCS, TNFa, IFNg,) were determined using ELISA kit (Human ultrasensitive cytokine 10 -plex panel [Invitrogen, CA, USA]). GS and PD ultrasound was assessed in 7 joints according to Backhaus et al (2). Esaote MyLab ® 25 ultrasound machine with 12-18 MHz linear probe was used. Results 21 patients were included. Clinical and demographic data are shown in the table. N=21 Age (years) 44.81 (25–69) Disease duration (months) 100.76 (28–353) Duration in clinical remission (months) 12.15 (1–43) DAS28 1.35 (0.99–2.42) Rheumatoid factor (positive) 95% (n=20) antiCCP (positive) 52% (n=11) GS synovitis was found in 95%, and tenosynovitis in 9.5%. PD was detected in 57%. There was no association between DAS28 and duration in clinical remission, disease duration and US-defined active synovitis (p=0.84, 0.309 and 0.762 respectively). Pro-inflammatory cytokines levels were elevated in patients with less than 6 months and in those with 13 to 24 months in clinical remission. Nevertheless, there was no correlation with US-defined synovitis (p=NS) Conclusions US detected a high percentage of subclinical synovitis in RA patients in clinical remission. Cytokine levels did not correlate with DAS 28 or ultrasound-defined active synovitis. References Brown AK, Conaghan P, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continues structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008; 58(10): 2958-2967 Backhaus M, Ohrndorf S, Kellner H, et al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum 2009; 61(9): 1194-1201 Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.4855